Submitted by: Submitted by kksingha
Views: 10
Words: 1034
Pages: 5
Category: Business and Industry
Date Submitted: 12/16/2015 05:37 AM
Postmenopausal Vaginal Atrophy PVA Drugs Single User License:
Market - Global Industry Analysis, Size, Share, USD 4315.5
Growth, Trends and Forecast 2015 - 2023
Flat 10% Discount!!
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
www.transparencymarketresearch.com
sales@transparencymarketresearch.com
Free Customization as per your requirement
You will get Custom Report at Syndicated Report
price
Report will be delivered with in 15-20 working days
Request Sample
Buy Now
REPORT DESCRIPTION
Postmenopausal Vaginal Atrophy (PVA) refers to decrease in estrogen production most commonly after menopause and the condition is also
called as vaginal Atrophy. Less estrogen leads to drying, thinning, and decreased elasticity of vaginal tissues. Various other causes leading to
decrease in estrogen levels include perimenopause, during breast feeding, surgical menopause, pelvic radiation therapy and chemotherapy and
also as a side effect of breast cancer hormonal treatment. Symptoms of vaginal Atrophy include burning, redness, itching, dyspareuia, and
irritation. Vaginal atrophy is a common result of the treatment of many gynecological cancers. Postmenopausal vaginal Atrophy is known to occur
commonly due to increase in life expectancy and lengthening of average lifespan post menopause. Diagnosis for PVA includes pelvic examination,
vaginal smear test, vaginal activity test, blood test and urine test.
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/postmenopausal-vaginal-atrophy-pva-drugs-market.html
The treatment generally involves use of hormonal replacement therapy, estrogen creams, pessaries or lubricating gels. The sensitivity of
urogenital tract to the decline in estrogen levels leads to symptoms related to vaginal atrophy, and is also known to affect sexual function and
quality of life in about half of all postmenopausal women. Most commonly, vaginal atrophy becomes evident 4–5 years...